Arecor Therapeutics PLC ARECOR COMMENCES US PHASE I TRIAL OF AT247 (0217Z)
January 20 2022 - 1:00AM
UK Regulatory
TIDMAREC
RNS Number : 0217Z
Arecor Therapeutics PLC
20 January 2022
Arecor Therapeutics plc
("Arecor" or the "Group")
ARECOR COMMENCES US PHASE I CLINICAL TRIAL OF AT247 ULTRA-RAPID
INSULIN IN COMBINATION WITH AN INSULIN PUMP
First patient dosed in potential game-changing diabetes
combination therapy
Cambridge, UK, 20 January 2022: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives, today announces that it has commenced the
US
Phase I clinical trial of Arecor's lead product, AT247, an
ultra-rapid insulin to be delivered by continuous subcutaneous
infusion via insulin pump over a period of three days.
The trial is a double blind, randomised, three-way crossover
study comparing the pharmacokinetics (PK) and pharmacodynamics (PD)
of AT247 with Novo Nordisk's NovoRapid(R) and Fiasp(R), two
market-leading rapid acting insulin treatments in 24 participants
with type I diabetes. It will be the first trial to investigate the
product's potential when delivered by continuous subcutaneous
infusion via insulin pump over a period of three days and follows a
previous successful first-in-man clinical study.
AT247, a novel proprietary formulation of insulin, aims to
accelerate insulin absorption, post injection, to enable more
effective management of blood glucose levels for people living with
diabetes. AT247 has the potential to significantly improve post
prandial glucose control so avoiding episodes of both hypo and
hyperglycemia. In a European Phase I clinical study in Type I
diabetic patients published in 2021, AT247 exhibited an earlier
insulin appearance, exposure, and offset, with corresponding
enhanced early glucose-lowering effect compared with NovoRapid(R)
and Fiasp(R). This new trial is targeted for completion in H2 2022
and is expected to provide additional evidence that AT247 has the
potential to facilitate a fully closed loop artificial pancreas, a
potentially life changing treatment option for people living with
diabetes.
Sarah Howell, Chief Executive Officer of Arecor, said: "We are
excited to be initiating our first US clinical study that has been
designed to further demonstrate the superiority of AT247 compared
to current best-in-class insulins available to patients on the
market today. Understanding the characteristics of AT247 when
delivered via an infusion pump is important and may facilitate a
fully closed loop artificial pancreas, transforming the lives of
the c.537 million people living with diabetes."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014 (MAR)
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700
Gray Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary formulation technology
platform, Arestat(TM), we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat(TM) platform is supported by an extensive patent
portfolio.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBKCBQKBKBADD
(END) Dow Jones Newswires
January 20, 2022 02:00 ET (07:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Apr 2024 to May 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From May 2023 to May 2024